| scholarly article | Q13442814 |
| P50 | author | Su-Xia Han | Q81564545 |
| P2093 | author name string | Mei Liu | |
| Jian-Ying Zhang | |||
| Qing Zhu | |||
| Yusen Zhou | |||
| Hua Ye | |||
| Liping Dai | |||
| Xia Ying | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma | Q24318952 | ||
| CIP2A inhibits PP2A in human malignancies | Q24319683 | ||
| A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma | Q24322614 | ||
| Human neoplasms elicit multiple specific immune responses in the autologous host | Q24564371 | ||
| Isolation and analysis of cDNA clones expressing human lupus La antigen | Q24568042 | ||
| A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma | Q24676730 | ||
| Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells | Q28237550 | ||
| From genomics to proteomics | Q30482453 | ||
| Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis | Q30713843 | ||
| Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. | Q31126879 | ||
| De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma | Q31938591 | ||
| The sentinel within: exploiting the immune system for cancer biomarkers | Q33221191 | ||
| Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis | Q33376017 | ||
| Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma | Q33493776 | ||
| Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma | Q33881201 | ||
| p53 Antibodies in the sera of patients with various types of cancer: a review | Q33892337 | ||
| Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. | Q34138916 | ||
| An overview of the mechanisms of mutagenesis and carcinogenesis | Q34279679 | ||
| The multistep nature of cancer | Q34366937 | ||
| Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis | Q35059164 | ||
| Identification of tumor-associated antigens using proteomics | Q35081121 | ||
| Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology | Q35205810 | ||
| Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers | Q35754783 | ||
| Why is Hu where? Shuttling of early-response-gene messenger RNA subsets | Q35965031 | ||
| Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis | Q36169087 | ||
| A survey of the humoral immune response of cancer patients to a panel of human tumor antigens | Q36400634 | ||
| Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis | Q36721517 | ||
| Autoantibodies to tumor-associated antigens: reporters from the immune system | Q37118192 | ||
| Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma | Q37187763 | ||
| Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. | Q37252915 | ||
| Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors | Q37724875 | ||
| Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. | Q40282641 | ||
| Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis | Q40511437 | ||
| Autoantibodies in viral hepatitis-related hepatocellular carcinoma | Q40863151 | ||
| Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation | Q41612390 | ||
| New paths in human cancer serology | Q41821668 | ||
| Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis | Q42555303 | ||
| Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer | Q45263174 | ||
| Recursive partitioning as an approach to selection of immune markers for tumor diagnosis | Q46135231 | ||
| Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. | Q46821034 | ||
| Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. | Q50535152 | ||
| Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma | Q72940041 | ||
| High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer | Q73863091 | ||
| A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis | Q74405612 | ||
| P433 | issue | 12 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1123-1128 | |
| P577 | publication date | 2013-06-24 | |
| P1433 | published in | Autoimmunity Reviews | Q15754966 |
| P1476 | title | Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis | |
| P478 | volume | 12 |
| Q33648667 | Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma |
| Q37635618 | Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. |
| Q38452333 | Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma |
| Q35793861 | Autoimmune response to PARP and BRCA1/BRCA2 in cancer |
| Q38211189 | Autoimmunity in 2013. |
| Q64235860 | CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment |
| Q89457572 | Establishment and validation of an immunodiagnostic model for prediction of breast cancer |
| Q41709447 | Evaluation of autoantibody signatures in meningioma patients using human proteome arrays |
| Q49419816 | Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality |
| Q38782056 | Natural Antibodies to Tumor-Associated Antigens |
| Q48505124 | Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers |
| Q39438407 | Secreted tumor antigens - immune biomarkers for diagnosis and therapy. |
| Q36102628 | Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients |
| Q36921385 | The Widening Sphere of Influence of HOXB7 in Solid Tumors |
| Q46941311 | Unique topics and issues in rheumatology and clinical immunology |
Search more.